1. Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial. Issue 10222 (8th February 2020) Authors: Ritchlin, Christopher T; Kavanaugh, Arthur; Merola, Joseph F; Schett, Georg; Scher, Jose U; Warren, Richard B; Gottlieb, Alice B; Assudani, Deepak; Bedford-Rice, Kathy; Coarse, Jason; Ink, Barbara; McInnes, Iain B Journal: Lancet Issue: Volume 395:Issue 10222(2019) Page Start: 427 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗